The US Preventive Services Task Force (USPSTF) has given thyroid cancer screening a D grade, recommending against screening.1 They conclude with moderate certainty that screening for thyroid cancer in asymptomatic persons results in harms that outweigh the benefits. Given the historical context—both in pathology and medical care epidemiology—it should have been an easy decision.
Welch HG. Cancer Screening, Overdiagnosis, and Regulatory Capture. JAMA Intern Med. 2017;177(7):915–916. doi:10.1001/jamainternmed.2017.1198
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: